Dr. Thompson is a Professor of Medicine at UC Davis Health Medical Center with a joint appointment in Internal Medicine, Division of Infectious Diseases and the Department of Medical Microbiology and Immunology. Dr. Thompson specializes in the care of patients with invasive fungal infections and has research interest in clinical trials, fungal diagnostics, and host immunogenetics. His current research focuses on the development of new antifungal agents, mechanisms of resistance, and molecular causes of adverse side effects. Dr. Thompson has published over 180 papers in peer-reviewed journals, and serves as several national and international committees and advisory boards including the IDSA, Coccidioidomycosis Study Group and the Mycoses Study Group where he chairs the education committee.
B.S., University of Missouri, Columbia MO 1999
M.D., University of Missouri, Columbia MO 2003
Internal Medicine, University of Texas, San Antonio TX 2003-2004
Internal Medicine, University of Texas, San Antonio TX 2004-2006
Chief Resident, University of Texas, San Antonio TX 2006-2007
Infectious Diseases, University of Texas, San Antonio TX 2007-2009
Internal Medicine Outstanding Clinician Award, UC Davis, 2021
Sacramento Top Doctors, Infectious Diseases, 2018, 2019, 2020, 2021
Top 10 Papers that will change your clinical practice, IDWeek, Washington DC, 2019
Internal Medicine Faculty Research Award, UC Davis, 2017
Outstanding Young Physician Award, University of Missouri School of Medicine, 2014
Bays DJ, Thompson GR, Reef S, Snyder L, Freifeld AJ, Huppert M, Salkin D, Wilson MD, Galgiani JN. Natural History of Disseminated Coccidioidomycosis: Examination of the Veterans Affairs-Armed Forces Database. Clin Infect Dis. 2021 Dec 6;73(11):e3814-e3819. doi:10.1093/cid/ciaa1154. PMID:32778863.
Thompson GR, Soriano A, Skoutelis A, Vazquez JA, Honore PM, Horcajada JP, Spapen H, Bassetti M, Ostrosky-Zeichner L, Das AF, Viani RM, Sandison T, Pappas PG. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clin Infect Dis. 2021 Dec 6;73(11):e3647-e3655. doi:10.1093/cid/ciaa1380. Erratum in: Clin Infect Dis. 2021 Aug 2;73(3):561-562. PMID:32955088.
Thompson GR 3rd, Young JH. Aspergillus Infections. N Engl J Med. 2021 Oct 14;385(16):1496-1509. doi:10.1056/NEJMra2027424. PMID:34644473.
Thompson GR 3rd, Le T, Chindamporn A, et al. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. Lancet Infect Dis. 2021 Aug 5. doi:10.1016/S1473-3099(21)00191-2. PMID:34364529. Correction: Lancet Infect Dis. 2021 Nov 1;21(11):E341. doi.org/10.1016/S1473-3099(21)00588-0.
Nguyen MH, Davis MR, Wittenberg R, Mchardy I, Baddley JW, Young BY, Odermatt A, Thompson GR. Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism. Clin Infect Dis. 2020 Jun 10;70(12):2593-2598. doi:10.1093/cid/ciz741. PMID:31403165.
Thompson GR 3rd, Beck KR, Patt M, Kratschmar DV, Odermatt A. Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2. J Endocr Soc. 2019 Jun 6;3(7):1361-1366. doi:10.1210/js.2019-00189. PMID:31286100.
Stockamp NW, Thompson GR 3rd. Coccidioidomycosis. Infect Dis Clin North Am. 2016 Mar;30(1):229-46. doi:10.1016/j.idc.2015.10.008. Epub 2015 Dec 29. PMID:26739609.